India · Delayed Price · Currency is INR Piramal Pharma Statistics
Total Valuation
Piramal Pharma has a market cap or net worth of INR 309.45 billion. The enterprise value is 360.11 billion.
| Market Cap | 309.45B |
| Enterprise Value | 360.11B |
Important Dates
The last earnings date was Tuesday, October 27, 2026.
| Earnings Date | Oct 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 1.33B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.50% |
| Shares Change (QoQ) | +4.54% |
| Owned by Insiders (%) | 0.09% |
| Owned by Institutions (%) | 21.71% |
| Float | 614.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 80.00 |
| PS Ratio | 3.16 |
| PB Ratio | 3.79 |
| P/TBV Ratio | 8.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 26.82 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.68 |
| EV / EBITDA | 29.47 |
| EV / EBIT | 95.06 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.72.
| Current Ratio | 1.41 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 5.06 |
| Debt / FCF | n/a |
| Interest Coverage | 0.92 |
Financial Efficiency
Return on equity (ROE) is -2.58% and return on invested capital (ROIC) is -22.17%.
| Return on Equity (ROE) | -2.58% |
| Return on Assets (ROA) | 1.14% |
| Return on Invested Capital (ROIC) | -22.17% |
| Return on Capital Employed (ROCE) | 2.37% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 13.73M |
| Profits Per Employee | -293,287 |
| Employee Count | 7,120 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Piramal Pharma has paid 2.33 billion in taxes.
| Income Tax | 2.33B |
| Effective Tax Rate | 997.81% |
Stock Price Statistics
The stock price has increased by +14.57% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +14.57% |
| 50-Day Moving Average | 206.73 |
| 200-Day Moving Average | 176.41 |
| Relative Strength Index (RSI) | 71.83 |
| Average Volume (20 Days) | 623,519 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Piramal Pharma had revenue of INR 97.79 billion and -2.09 billion in losses. Loss per share was -1.57.
| Revenue | 97.79B |
| Gross Profit | 58.39B |
| Operating Income | 3.18B |
| Pretax Income | 233.20M |
| Net Income | -2.09B |
| EBITDA | 11.05B |
| EBIT | 3.18B |
| Loss Per Share | -1.57 |
Balance Sheet
The company has 8.30 billion in cash and 58.73 billion in debt, with a net cash position of -50.43 billion.
| Cash & Cash Equivalents | 8.30B |
| Total Debt | 58.73B |
| Net Cash | -50.43B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 81.65B |
| Book Value Per Share | 58.37 |
| Working Capital | 20.95B |
Cash Flow
In the last 12 months, operating cash flow was 11.54 billion and capital expenditures -13.15 billion, giving a free cash flow of -1.62 billion.
| Operating Cash Flow | 11.54B |
| Capital Expenditures | -13.15B |
| Depreciation & Amortization | 7.87B |
| Net Borrowing | 5.10B |
| Free Cash Flow | -1.62B |
| FCF Per Share | n/a |
Margins
Gross margin is 59.71%, with operating and profit margins of 3.25% and -2.14%.
| Gross Margin | 59.71% |
| Operating Margin | 3.25% |
| Pretax Margin | 0.24% |
| Profit Margin | -2.14% |
| EBITDA Margin | 11.30% |
| EBIT Margin | 3.25% |
| FCF Margin | n/a |
Dividends & Yields
Piramal Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -0.50% |
| Shareholder Yield | -0.50% |
| Earnings Yield | -0.67% |
| FCF Yield | -0.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Piramal Pharma is 250.55, which is 7.63% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 250.55 |
| Price Target Difference | 7.63% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 15.34% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |